Cargando…
Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor
Lymphangioleiomyomatosis (LAM) is a rare metastatic cystic lung disease due to a mutation in a TSC tumor suppressor, resulting in hyperactive mTOR growth pathways. Sirolimus (rapamycin), an allosteric mTORC1 inhibitor, is a therapeutic option for women with LAM but it only maintains lung volume duri...
Autores principales: | Evans, Jilly F., Rue, Ryan W., Mukhitov, Alexander R., Obraztsova, Kseniya, Smith, Carly J., Krymskaya, Vera P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022412/ https://www.ncbi.nlm.nih.gov/pubmed/31878201 http://dx.doi.org/10.3390/biom10010028 |
Ejemplares similares
-
Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells
por: Himes, Blanca E., et al.
Publicado: (2018) -
Syndecan-2: Old Player in a New Field
por: Obraztsova, Kseniya, et al.
Publicado: (2019) -
CrossTORC and WNTegration in Disease: Focus on Lymphangioleiomyomatosis
por: Evans, Jilly Frances, et al.
Publicado: (2021) -
Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
por: Evans, Jilly F., et al.
Publicado: (2023) -
Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
por: Mrozek, Evelyn M., et al.
Publicado: (2021)